GSK wins FDA accelerated approval for Nelkarmi in previously treated ALK-positive lung cancer
GSK•The FDA granted accelerated approval to GSK’s Nelkarmi for adults with previously treated advanced ALK-positive non-small cell lung cancer. The decision came ahead of the agency’s November 27, 2026, target action date.
1. FDA approval
The FDA granted accelerated approval to GSK’s Nelkarmi for adults with previously treated advanced ALK-positive non-small cell lung cancer. The decision came ahead of the agency’s original November 27, 2026, target action date.




